NAOV - NanoVibronix, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.0700
+0.0700 (+3.50%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close2.0000
Open2.2800
Bid0.0000 x 3000
Ask0.0000 x 1000
Day's Range2.0196 - 2.2900
52 Week Range1.4200 - 4.2000
Volume8,577
Avg. Volume11,406
Market Cap8.929M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.3780
Earnings DateJun 29, 2020 - Jun 30, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    SANUWAVE Health Announces Exclusive Licensing of NanoVibronix, Inc. Surface Acoustic Wave Ultrasound Technology

    SUWANEE, GA, April 02, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV) and NanoVibronix, Inc. have announced an exclusive worldwide license agreement for NanoVibronix’s surface acoustic wave ultrasound technology in the wound care market. Under this agreement, SANUWAVE has acquired the exclusive worldwide license and sales rights for NanoVibronix’s patch-based therapeutic ultrasound technology device, WoundShield®, that facilitates tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. SANUWAVE will seek regulatory approval of WoundShield® in Europe and the United States and NanoVibronix shall maintain the sole right to manufacture the licensed products.

  • NanoVibronix Announces License Agreement for WoundShield Product
    PR Newswire

    NanoVibronix Announces License Agreement for WoundShield Product

    NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield®, and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it signed a license agreement with Sanuwave Health, Inc. for the manufacture and delivery of its WoundShield technology.

  • GlobeNewswire

    NanoVibronix Receives Reimbursement Approval from U.S. Centers for Medicare & Medicaid Services (CMS) for PainShield™

    NanoVibronix, Inc., (NAOV), a medical device company that produces the PainShield® Surface Acoustic Wave (SAW) Portable Ultra Sonic therapeutic device, today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has approved its PainShield™ for reimbursement for Medicare beneficiaries on a national basis effective January 2020. “PainShield provides an effective alternative to pharmaceuticals for pain management and can be used in a variety of settings including the safety of a patient’s home, which has become increasingly important in light of the coronavirus (COVID-19) pandemic,” said Brian Murphy, CEO of NanoVibronix.

  • GlobeNewswire

    NanoVibronix looks to expand use of its UroShield Due to the potential to impact comorbidities related to COVID-19 Crisis

    NanoVibronix, Inc., (NAOV), a medical device company that produces the UroShield® Surface Acoustic Wave (SAW) Portable Ultra Sonic therapeutic device which attaches to an indwelling catheter and has been clinically proven to mitigate Catheter Associated Urinary Tract Infection (CAUTI), as well as reducing pain and blockages, today announced that it has reached out to regulatory agencies around the world to inform them of the potential benefits for greater use of the product on compromised patients. As a result of the COVID-19 crisis, critically ill patients are at the greatest risk, especially when compromised by comorbidities, such as CAUTI.

  • ACCESSWIRE

    NanoVibronix, Inc. to Present at the Investor Summit on December 17th in Philadelphia

    PHILADELPHIA, PA / ACCESSWIRE / December 10, 2019 / NanoVibronix, Inc. (NASDAQ:NAOV), will be presenting at this year's Investor Summit on December 17 th in Philadelphia. The Investor Summit will take ...

  • PR Newswire

    NanoVibronix Provides Business Update for the Third Quarter of 2019

    ELMSFORD, N.Y., Nov. 19, 2019 /PRNewswire/ -- NanoVibronix, Inc., (NAOV), a medical device company that produces the PainShield® Surface Acoustic Wave (SAW) Portable Ultra Sonic therapeutic device, today provided a business update for the third quarter ended September 30, 2019. "This has been a productive and important quarter for NanoVibronix, positioning us for accelerating growth in 2020 and beyond," commented Brian Murphy, CEO of NanoVibronix. Simultaneously, we have broadened our distribution channels, adding key partners to directly target key potential customers, including the Federal Supply Schedule and CMS/Medicare, and we are making progress in our efforts to target the Veterans Administration and European customers through private label arrangements.

  • PR Newswire

    NanoVibronix PainShield® Device Receives Unique Reimbursement Code from Centers for Medicare and Medicaid (CMS)

    ELMSFORD, N.Y., Nov. 18, 2019 /PRNewswire/ -- NanoVibronix, Inc., (NAOV), a medical device company that produces the PainShield® Surface Acoustic Wave (SAW) Portable Ultra Sonic therapeutic device, today announced that the Centers for Medicare and Medicaid (CMS) has assigned a unique, Level II product reimbursement code under the Healthcare Common Procedure Coding System (HCPCS) for use in 2020. HCPCS code K1004 will help facilitate reimbursement for the use of PainShield.

  • NAOV: Q2 2019 Results / Business Update
    Zacks Small Cap Research

    NAOV: Q2 2019 Results / Business Update

    By Brian Marckx, CFA NASDAQ:NAOV READ THE FULL NAOV RESEARCH REPORT NanoVibronix (NASDAQ:NAOV) turned in a solid performance in Q2 (ending June 30, 2019) on both a financial and operational perspective. Highlights on the financial side include setting record highs on total revenue, PainShield revenue and UroShield revenue, gross margin (78.7%) at the widest level for at least the last 14 quarters

  • PR Newswire

    NanoVibronix and Marathon Medical to Provide PainShield to VA Hospitals and the Department of Justice

    ELMSFORD, N.Y., Sept. 3, 2019 /PRNewswire/ -- NanoVibronix, Inc., (NAOV), a medical device company that produces the PainShield® Surface Acoustic Wave (SAW) Portable Ultra Sonic therapeutic device, announces on August 18th, 2019, PainShield, and PainShield Supplies were added to the Federal Supply Schedule through NanoVibronix' relationship with Marathon Medical, a Service Disabled Veteran Owned Small Business (SDVOSB) headquartered in Aurora, Colorado. The Veterans Health Administration (VA) has launched an Opioid Safety Initiative (OSI), designed to address the growing epidemic of opioid misuse and opioid use disorder in America.

  • PR Newswire

    NanoVibronix Reports Significant Progress with a Leading Global Consumer Healthcare Company

    ELMSFORD, N.Y., Aug. 27, 2019 /PRNewswire/ -- NanoVibronix, Inc., (NAOV), a medical device company that produces the PainShield® surface acoustic wave (SAW) device, today announced significant progress with a leading global consumer healthcare company, Medisana, which has resulted in an initial Original Equipment Manufacturing (OEM) purchase order. The Company will commence the manufacture of a specialized product for Medisana based on its PainShield® device called the PT-100. The product will be sold directly and exclusively via Medisana.

  • ACCESSWIRE

    NanoVibronix Signs Distribution Agreement with ProTrade Systems for PainShield(R) MD

    ELMSFORD, NY / ACCESSWIRE / August 13, 2019 / NanoVibronix, Inc., (NAOV), a medical device company that produces the PainShield® surface acoustic wave (SAW) device, which utilizes the Company’s proprietary and patented low intensity, SAW (Surface Acoustic Wave) ultrasound technology, today announced that it has signed a distribution agreement with ProTrade Systems, a medical equipment distributor in the U.S. for thousands of patients, elite athletes, athletic trainers, professional teams, special military forces, orthopedic surgeons, sports medicine doctors, and physical therapists. PainShield MD is a wearable therapeutic ultrasound device, which emits low level, low frequency therapeutic ultrasound to deliver fast pain relief for nerve and facilitating soft tissue repair.

  • ACCESSWIRE

    NanoVibronix Announces License Agreement with Ideal Medical International Limited for International Distribution of PainShield(R) and UroShield(R)

    ELMSFORD, NY / ACCESSWIRE / July 23, 2019 / NanoVibronix, Inc., (NAOV), a medical device company that produces the PainShield® surface acoustic wave (SAW) device, which utilizes the Company’s proprietary and patented low intensity, SAW ultrasound technology, today announced that it has entered into an non-exclusive license agreement with Ideal Medical International Limited pursuant to which Ideal Medical International Limited will serve as a non-exclusive international distributor for UroShield® and PainShield® in various regions around the world. Ideal Medical International Limited is a wholly owned subsidiary of IMS (International Medical Supplies) Euro, a leading international supplier of medical products.

  • GlobeNewswire

    NanoVibronix Announces Closing of $3.2 Million Private Placement

    NanoVibronix, Inc., (NAOV), a medical device company that produces the PainShield® surface acoustic wave (SAW) device, which utilizes the Company’s proprietary and patented low intensity, SAW ultrasound technology, today announced that it closed a private placement transaction in which it issued and sold to existing stockholders 1.6 million Series E convertible preferred stock and 1.6 million 7-year warrants to purchase Series E convertible preferred stock at a price of $2.50 per share for gross proceeds to the Company of $3.2 million. The Series E convertible preferred shares are convertible into shares of common stock on a one-for-one basis. The Company plans to submit to stockholders for approval, within 90 days of the closing of the private placement, the issuance of the shares of common stock issuable upon conversion of the Series E preferred stock, in accordance with the rules of the Nasdaq Stock Market.

  • ACCESSWIRE

    NanoVibronix Announces Presentation of PainShield(R) to HCPCS Workgroup at CMS

    ELMSFORD, NY / ACCESSWIRE / June 19, 2019 / NanoVibronix, Inc., (NAOV), a medical device company that produces the PainShield® surface acoustic wave (SAW) device, which utilizes the Company's proprietary and patented low intensity, SAW ultrasound technology, announces that on June 12, 2019, the Company had the opportunity to present their signature product, PainShield® surface acoustic wave device, to the Healthcare Common Procedure Coding System (HCPCS) Workgroup at the Centers for Medicare & Medicaid Services (CMS) offices in Baltimore, Maryland. The HCPCS Workgroup is tasked with evaluating products, supplies, and services that are not included in the Current Procedural Terminology (CPT) codes, such as ambulance services and durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) when used outside a physician's office, as well as recommending appropriate payment by the Medicare and Medicaid payment systems.

  • ACCESSWIRE

    NanoVibronix Announces Rescheduling of Annual Meeting of Stockholders

    ELMSFORD, NY / ACCESSWIRE / June 14, 2019 / NanoVibronix, Inc., (NAOV), a medical device company that produces the PainShield® surface acoustic wave (SAW) device, which utilizes the Company's proprietary and patented low intensity, SAW ultrasound technology, announces that the Company's 2019 Annual Meeting of Stockholders, originally scheduled for 10:00 a.m. Eastern Time yesterday, June 13, 2019, was adjourned due to the lack of the requisite quorum. During the period of the adjournment, the Company will continue to solicit proxies from its stockholders with respect to the proposals set forth in the Company's proxy statement. The Company encourages all stockholders who have not yet voted to do so before June 19, 2019 at 11.59 p.m. Eastern time.

  • Benzinga

    NanoVibronix Announces Planned Launch Of CBD Patch, Cream

    Nanocap medical device company NanoVibronix (NASDAQ: NAOV ) announced it's developing cannabidiol patches and cream utilizing a proprietary and nanoparticle-based infusion process. CBD is one of the naturally ...

  • GlobeNewswire

    NanoVibronix Announces Planned Launch of CBD Patch and Cream for PainShield® Designed to Amplify Therapeutic Effect

    ELMSFORD, N.Y., June 05, 2019 (GLOBE NEWSWIRE) --  NanoVibronix, Inc., (NAOV), a medical device company that produces the PainShield® surface acoustic wave (SAW) device, which utilizes the Company’s proprietary and patented low intensity, SAW ultrasound technology, today announced that it is developing a cannabidiol (CBD) patch and cream utilizing a proprietary and nanoparticle-based infusion process.  NanoVibronix intends to make the CBD patch as well as similarly formulated CBD cream available in combination with PainShield® as PainShield CBD™. NanoVibronix intends to demonstrate that coupling the infused patch and cream with PainShield® will increase absorption and may provide sustained pain relief for up to 24 hours.  The Company believes that this will be the first known ultrasound-based pain relief product available in combination with CBD, which can be used at home, and outside of a clinical setting, as an opioid-alternative.

  • Zacks Small Cap Research

    NAOV: Several Major Milestones Expected This Year Including FDA Filings for OTC PainShield, UroShield

    NanoVibronix (NAOV) filed their 10-Q for Q1 2019 ending March 31st and released a corresponding business update. OTC approval, if and when achieved, would be a major milestone as it would allow for purchase and use of PainShield without the need for a doctor’s prescription – which has been a major impediment to sales to-date.